Healthcare Congressional Oversight 2026

A congressional staffer sits at a desk in 2026, not November, not after the midterms.
They are already requesting that companies preserve information. Already cultivating external sources. Already drafting investigative frameworks.

This is the reality according to Healthcare Dive, citing attorneys from Holland and Knight’s Washington, D.C., office.

Congressional Democrats are planning investigations into major healthcare topics if they win majorities in the 120th Congress this November. But the preparation is not waiting for election results.

Here is what they are targeting:
• Drug pricing strategies and manufacturer price increases
• Insurance premium increases and cost-sharing structures
• Facility fees and billing practices
• Compliance with the No Surprises Act
• Medical debt collection and credit reporting practices
• Private equity ownership in hospitals, nursing homes, and specialty practices
• Hospital acquisitions, closures, and real estate investment structures involving healthcare facilities
• Staffing reductions following acquisitions

The scope is broader than it looks.

Past oversight focused narrowly on affordability and fraud. That remains the organizing principle, but the next wave adds scrutiny of regulatory decision-making, federal contracting, and the relationships between industry and political appointees in the Trump administration.

Private equity in healthcare is now squarely in the crosshairs. Building on prior investigations into nursing homes, emergency physician staffing groups, and specialty practices, future inquiries will examine whether financial ownership structures negatively affect patient care, staffing levels, service availability, and long-term system stability.

Three perspectives worth holding at the same time:

For health system leaders: The risk is not just legal. Reputational and political exposure are equally real. Companies that wait until after the election to assess exposure may find themselves responding to congressional inquiries under compressed timelines.

For digital health and health tech companies: This is not aimed only at big incumbents. Trade associations, consultants, investors, and contractors that interact with federal healthcare programs are explicitly named as targets of heightened scrutiny.

For patients: Affordability, medical debt, surprise billing, and prescription drug costs remain the dominant political organizing principle across both parties. That consistency is the one thing that does not change when control shifts.

The ACCESS Framework: Evaluating Your Oversight Exposure

Before the election, run your organization through these five questions:
• Affordability: Do your pricing, billing, or cost-sharing practices create visible patient harm?
• Contracting: Do you have federal contracts or financial relationships with political appointees?
• Consolidation: Have you acquired hospitals, practices, or facilities in the past three years?
• Equity structure: Is private equity in your ownership chain, and how does it affect staffing?
• Surprises: Are you in compliance with the No Surprises Act, fully and documentably?

If you cannot answer each of these cleanly, you have work to do before November.

Worth saving before your next board discussion on regulatory risk.

My honest read: healthcare oversight has always been bipartisan in theory. In practice, it moves in cycles tied to political power. What is different now is the pre-positioning. Investigators building frameworks before an election has even been decided signals that this is not a reactive exercise. It is a strategic one. The healthcare organizations that treat this as a future problem will find it becomes a very present one very fast.

👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com